These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 11243272)

  • 1. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy.
    Shields RC; McBane RD; Kuiper JD; Li H; Heit JA
    Mayo Clin Proc; 2001 Mar; 76(3):260-6. PubMed ID: 11243272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study.
    Lubetsky A; Yonath H; Olchovsky D; Loebstein R; Halkin H; Ezra D
    Arch Intern Med; 2003 Nov; 163(20):2469-73. PubMed ID: 14609783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of oral versus intravenous phytonadione in patients with excessive anticoagulation.
    Key N
    Curr Hematol Rep; 2004 Sep; 3(5):315-6. PubMed ID: 15341696
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis.
    Dezee KJ; Shimeall WT; Douglas KM; Shumway NM; O'malley PG
    Arch Intern Med; 2006 Feb; 166(4):391-7. PubMed ID: 16505257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation.
    Pengo V; Banzato A; Garelli E; Zasso A; Biasiolo A
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):739-41. PubMed ID: 8292723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting.
    Tsu LV; Dienes JE; Dager WE
    Ann Pharmacother; 2012 Dec; 46(12):1617-26. PubMed ID: 23249867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Intravenous Versus Subcutaneous Phytonadione on Length of Stay for Patients in Need of Urgent Warfarin Reversal.
    Mottice BL; Soric MM; Legros E
    Am J Ther; 2016; 23(2):e345-9. PubMed ID: 25461960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation.
    Patel RJ; Witt DM; Saseen JJ; Tillman DJ; Wilkinson DS
    Pharmacotherapy; 2000 Oct; 20(10):1159-66. PubMed ID: 11034038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione.
    Raj G; Kumar R; McKinney WP
    Arch Intern Med; 1999 Dec 13-27; 159(22):2721-4. PubMed ID: 10597763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
    Yasaka M; Sakata T; Naritomi H; Minematsu K
    Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective evaluation of vitamin K1 therapy to reverse the anticoagulant effect of warfarin.
    Fan J; Armitstead JA; Adams AG; Davis GA
    Pharmacotherapy; 2003 Oct; 23(10):1245-50. PubMed ID: 14594342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.
    Larson BJ; Zumberg MS; Kitchens CS
    Chest; 2005 Mar; 127(3):922-7. PubMed ID: 15764777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series.
    Schultz KT; Bungard TJ
    Pharmacotherapy; 2011 Aug; 31(8):793-805. PubMed ID: 21923606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.
    Liew A; Eikelboom JW; O'Donnell M; Hart RG
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S34-44. PubMed ID: 23790596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.
    Hylek EM; Chang YC; Skates SJ; Hughes RA; Singer DE
    Arch Intern Med; 2000 Jun; 160(11):1612-7. PubMed ID: 10847254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin.
    Crowther MA; Donovan D; Harrison L; McGinnis J; Ginsberg J
    Thromb Haemost; 1998 Jun; 79(6):1116-8. PubMed ID: 9657434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous phytonadione for reversal of warfarin-induced elevation of the International Normalized Ratio.
    Byrd DC; Stephens MA; Hamann GL; Dorko C
    Am J Health Syst Pharm; 1999 Nov; 56(22):2312-5. PubMed ID: 10582823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of warfarin reversal in orthopedic trauma surgery patients.
    Tharmarajah P; Pusey J; Keeling D; Willett K
    J Orthop Trauma; 2007 Jan; 21(1):26-30. PubMed ID: 17211265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.